not an expert statistics person , but I’ve posted a link before that explains futility analysis.
—- as I understand it a statistician has some sort of calculation that spits out a probability (of success / failure) for the final endpoint based on what ever is seen at interim in first few patients , in this case proteinuria difference.
—- it’s normally for the company to decide what is the lowest probability they’ll accept before deciding if it’s futile or not to keep trial going.
—- this will only apply to proteinurya endpoint not gfr as the futility in March appears to be on protein only
—-/ despite some other posters claims this has absolutely zilch to do with p value in the usual sense
Ann: Application for quotation of securities - DXB, page-95
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
0.035(6.67%) |
Mkt cap ! $308.1M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 57.3¢ | 50.5¢ | $2.179M | 3.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30558 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |